The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
Abstract
Purpose: To investigate whether hormonal receptors and human epidermal growth factor receptor 2 (HER2) change throughout tumor progression, because this may alter patient management. Patients and Methods: The study cohort included female patients with breast cancer in the Stockholm health care region who relapsed from January 1, 1997, to December 31, 2007. Either biochemical or immunohistochemical (IHC)/immunocytochemical (ICC) methods were used to determine estrogen receptor (ER), progesterone receptor (PR), and HER2 status, which was then confirmed by fluorescent in situ hybridization for IHC/ICC 2+ and 3+ status. Results: ER (459 patients), PR (430 patients), and HER2 (104 patients) from both primary tumor and relapse were assessed, revealing a change in 32.4% (McNemar's test P < .001), 40.7% (P < .001), and 14.5% (P = .44) of patients, respectively. Assessment of ER (119 patients), PR (116 patients), and HER2 (32 patients) with multiple (from two to six) consecutive relapses showed an alteration in 33.6%, 32.0%, and 15.7% of patients, respectively. A statistically significant differential overall survival related to intraindividual ER and PR status in primary tumor and relapse (log-rank P < .001) was noted. In addition, women with ER-positive primary tumors that changed to ER-negative tumors had a significant 48% increased risk of death (hazard ratio, 1.48; 95% CI, 1.08 to 2.05) compared with women with stable ER-positive tumors. Conclusion: Patients with breast cancer experience altered hormone receptor and HER2 status throughout tumor progression, possibly influenced by adjuvant therapies, which significantly influences survival. Hence, marker investigations at relapse may potentially improve patient management and survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dissemination and growth of cancer cells in metastatic sites
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc865 · Cited by 3,911
Partial residuals for the proportional hazards regression model
SCHOENFELD, D. (1982) · Biometrika · doi:10.1093/biomet/69.1.239 · Cited by 3,111
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,460
The pathogenesis of cancer metastasis
Poste, G., & Fidler, I. J. (1980) · Nature · doi:10.1038/283139a0 · Cited by 1,739
Metastasis Results from Preexisting Variant Cells Within a Malignant Tumor
Fidler, I. J., & Kripke, M. L. (1977) · Science · doi:10.1126/science.887927 · Cited by 1,425
Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations
Molina, R., Barak, V., van Dalen, A., Duffy, M. J., Einarsson, R., Gion, M., Goike, H., Lamerz, R., Nap, M., Sölétormos, G., et al. (2005) · Tumor Biology · doi:10.1159/000089260 · Cited by 334
Simmons, C., Miller, N., Geddie, W., Gianfelice, D., Oldfield, M., Dranitsaris, G., & Clemons, M. J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp028 · Cited by 286
Liedtke, C., Broglio, K., Moulder, S., Hsu, L., Kau, S.-W., Symmans, W. F., Albarracin, C., Meric-Bernstam, F., Woodward, W., Theriault, R. L., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp263 · Cited by 286
Thompson, A. M., Jordan, L. B., Quinlan, P., Anderson, E., Skene, A., Dewar, J. A., Purdie, C. A., & the Breast Recurrence in Tissues Study Group (2010) · Breast Cancer Research · doi:10.1186/bcr2771 · Cited by 253
Wu, J. M., Fackler, M. J., Halushka, M. K., Molavi, D. W., Taylor, M. E., Teo, W. W., Griffin, C., Fetting, J., Davidson, N. E., De Marzo, A. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4082 · Cited by 202
Broom, R. J., Tang, P. A., Simmons, C. E., Bordeleau, L. J., Mulligan, A. M., O’Malley, F. P., Miller, N. A., Andrulis, I. L., Brenner, D. M., & Clemons, M. J. (2009) · PubMed · Cited by 152
Guarneri, V., Giovannelli, S., Ficarra, G., Bettelli, S. R., Maiorana, A., Piacentini, F., Barbieri, E., Dieci, M. V., D’Amico, R., Jovic, G., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0048 · Cited by 150
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
Wilking, U., Karlsson, E., Skoog, L. K., Hatschek, T., Lidbrink, E. K., Elmberger, G., Johansson, H., Lindström, L. S., & Bergh, J. C. S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1029-2 · Cited by 122
Self-citationShould liver metastases of breast cancer be biopsied to improve treatment choice?
Curigliano, G., Bagnardi, V., Viale, G., Fumagalli, L. A. M., Rotmensz, N., Aurilio, G., Locatelli, M., Pruneri, G., Giudici, S., Bellomi, M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq751 · Cited by 117
Familial concordance in cancer survival: a Swedish population-based study
Lindström, L. S., Hall, P. N., Hartman, M., Wiklund, F., Grönberg, H., & Czene, K. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70282-6 · Cited by 78
Self-citationAmir, E., Ooi, W. S., Simmons, C. E., Kahn, H., Christakis, M. S., Popović, S., Kalina, M., Chesney, A. E., Singh, G., & Clemons, M. J. (2008) · Clinical Oncology · doi:10.1016/j.clon.2008.08.005 · Cited by 67
Khoshnoud, M. R., Löfdahl, B., Fohlin, H., Fornander, T., Stål, O., Skoog, L. K., Bergh, J. C. S., & Nordenskjöld, B. A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1202-7 · Cited by 59
Self-citationSneige, N. (2004) · Diagnostic Cytopathology · doi:10.1002/dc.20005 · Cited by 40
Marrazzo, A., Taormina, P., Leonardi, P., et al. (1995) · PubMed · Cited by 18
Cited by
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Tumour heterogeneity in the clinic
Bedard, P. L., Hansen, A. R., Ratain, M. J., & Siu, L. L. (2013) · Nature · doi:10.1038/nature12627 · Cited by 1,211
Breast cancer as a systemic disease: a view of metastasis
Redig, A. J., & McAllister, S. S. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12084 · Cited by 709
Tumor Heterogeneity in Breast Cancer
Turashvili, G., & Brogi, E. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00227 · Cited by 561
Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells
Keller, L., & Pantel, K. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0180-2 · Cited by 544
Metadata
- Authors
- Lindström, L. S., Karlsson, E., Wilking, U. M., Johansson, U., Hartman, J., Lidbrink, E. K., Hatschek, T., Skoog, L., & Bergh, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-07-20
- Volume
- 30
- Issue
- 21
- Pages
- 2601-2608
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2157434805
- Cited by
- 523
- References
- 21
- FWCI
- 13.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.